Summary:
A study to assess repeat treatment efficacy and safety of rifaximin 550 mg TID in subjects with irritable bowel syndrome with diarrhea (IBS-D).
Qualified Participants Must:
Be 18 years of age or older
Have been diagnosed with IBS-D
Have had a colonoscopy within the last 2 years